NeOnc's brain tumor drugs win first foreign clearances and near key data
First international regulatory clearance for NEO212 Abu Dhabi's health department authorized NeOnc to start a Phase 2 trial of NEO212, its oral brain tumor therapy. This is the program's first approval outside the U.S., opening a new region for testing and adding a fresh path toward eventual sales.
A brand-new regulatory milestone that expands the company's clinical reach and potential market.
Second Abu Dhabi clearance covers NEO100 and pediatric gliomas NeOnc received another Abu Dhabi IND for NEO100, allowing adult Phase 1 and 2 studies plus a path to test it in children with high-grade gliomas. This widens the number of patients and uses for its lead drug, raising its long-term sales potential.
A separate new authorization that broadens the NEO100 program into pediatrics and more trials.
FDA feedback clears CMC hurdle for NEO212 The FDA gave written feedback on how NeOnc makes NEO212, and the company decided it was enough to cancel a planned meeting. That removes a possible delay in the drug's manufacturing review, keeping the program on track toward later-stage testing.
A new regulatory step that reduces uncertainty around NEO212's path forward.
Phase 2a data for NEO100 due by end of July NeOnc's NEO100-01 study is fully enrolled, and topline Phase 2a results are expected by the end of July 2026. Positive data could boost confidence in the drug and attract partners or investors; disappointing results would hurt the stock.
A near-term catalyst that could swing the stock sharply depending on results.